About Cell Source
Cell Source is a company based in Tel Aviv (Israel) founded in 2011.. Cell Source has raised $397.5 thousand across 5 funding rounds. Cell Source offers products and services including Veto Cells and Cell Source Protocol. Cell Source operates in a competitive market with competitors including Enlivex Pharmaceuticals, Orgenesis, TissueGene, Sernova and LyGenesis, among others.
- Headquarter Tel Aviv, Israel
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cell Source, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-4.77 M10.34as on Dec 31, 2024
-
EBITDA
$-3.85 M7.99as on Dec 31, 2024
-
Total Equity Funding
$397.5 K (USD)
in 5 rounds
-
Latest Funding Round
$1.5 M (USD), Post-IPO
Jan 15, 2026
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cell Source
Cell Source is a publicly listed company on the OTC with ticker symbol CLCS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cell Source
Cell Source offers a comprehensive portfolio of products and services, including Veto Cells and Cell Source Protocol. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cells that target and eliminate anti-donor T-cells for safer transplants.
Protocol for stem cell transplantation without immunosuppression.
Funding Insights of Cell Source
Cell Source has successfully raised a total of $397.5K across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.5 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $1.5M
-
First Round
First Round
(27 Jul 2015)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Post-IPO - Cell Source | Valuation |
investors |
|
| Oct, 2023 | Amount | Post-IPO - Cell Source | Valuation |
investors |
|
| Oct, 2019 | Amount | Post-IPO - Cell Source | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Cell Source
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cell Source
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cell Source Comparisons
Competitors of Cell Source
Cell Source operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enlivex Pharmaceuticals, Orgenesis, TissueGene, Sernova and LyGenesis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Autologous and allogeneic cell immunotherapies are developed for autoimmune conditions.
|
|
| domain | founded_year | HQ Location |
Cell and gene therapies for multiple disorders are developed.
|
|
| domain | founded_year | HQ Location |
Regenerative cell therapies for orthopedic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Regenerative medicine to deliver proteins and hormones for disease treatment
|
|
| domain | founded_year | HQ Location |
Regenerative medicines for liver disorders are developed using lymph nodes.
|
|
| domain | founded_year | HQ Location |
Emmaus Medical is engaged in developing treatments for rare diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cell Source
Frequently Asked Questions about Cell Source
When was Cell Source founded?
Cell Source was founded in 2011 and raised its 1st funding round 4 years after it was founded.
Where is Cell Source located?
Cell Source is headquartered in Tel Aviv, Israel.
Is Cell Source a funded company?
Cell Source is a funded company, having raised a total of $397.5K across 5 funding rounds to date. The company's 1st funding round was a Post-IPO of $8.88M, raised on Jul 27, 2015.
What does Cell Source do?
Cell Source was founded in 2011 in Tel Aviv, Israel, where biotechnology cell therapies are developed to manage immune tolerance. White blood cells from patients or donors are processed into Veto Cells using cytokines to enable attacker-blocking functions. Bone marrow transplants are facilitated by Megadose through large stem cell doses from partially-matched donors. Pre-clinical programs include two Veto Cell applications for anti-rejection and anti-lymphoma, plus two Megadose-drug combinations.
Who are the top competitors of Cell Source?
Cell Source's top competitors include Enlivex Pharmaceuticals, Sernova and Emmaus Medical.
What products or services does Cell Source offer?
Cell Source offers Veto Cells and Cell Source Protocol.
Is Cell Source publicly traded?
Yes, Cell Source is publicly traded on OTC under the ticker symbol CLCS.
What is Cell Source's ticker symbol?
The ticker symbol of Cell Source is CLCS on OTC.